Patents by Inventor Jesus E. Gonzalez, III
Jesus E. Gonzalez, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8426201Abstract: A method of characterizing the biological activity of a candidate compound may include exposing cells to the candidate compound, and then exposing the cells to a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.Type: GrantFiled: September 28, 2009Date of Patent: April 23, 2013Assignee: Vertex Pharmaceuticals (San Diego) LLCInventors: Michael P. Maher, Jesus E. Gonzalez, III
-
Patent number: 8324220Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: GrantFiled: September 8, 2010Date of Patent: December 4, 2012Assignee: Vertex Pharmaceuticals IncorporatedInventors: Dean Mitchell Wilson, Esther Ann Martinborough, Timothy Donald Neubert, Andreas P. Termin, Jesus E. Gonzalez, III, Nicole Hilgraf
-
Patent number: 8309543Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: GrantFiled: May 23, 2012Date of Patent: November 13, 2012Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jesus E. Gonzalez, III, Andreas P. Termin, Esther Martinborough, Nicole Hilgraf
-
Publication number: 20120238578Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: ApplicationFiled: May 23, 2012Publication date: September 20, 2012Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Jesus E. Gonzalez, III, Andreas P. Termin, Esther Martinborough, Nicole Zimmerman
-
Publication number: 20120184583Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.Type: ApplicationFiled: April 4, 2011Publication date: July 19, 2012Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Frederick F. Van Goor, Sara Sabina Hadida-Ruah, Ashvani Kumar Singh, Eric R. Olson, Lewis Ray Makings, Jesus E. Gonzalez, III, James Arvid Rader, Fred Chambers, III, Mark Thomas Miller, Peter Diederik Jan Grootenhuis, Yahua Liu
-
Publication number: 20120040935Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: ApplicationFiled: May 18, 2011Publication date: February 16, 2012Applicant: Vertex Pharmaceuticals, Inc.Inventors: Dean M. Wilson, Andreas P. Termin, Timothy D. Neubert, Jian Wang, Yulian Zhang, Jesus E. Gonzalez, III, Esther Martinborough, Nicole Zimmerman
-
Patent number: 8071318Abstract: Drug candidate screening methods are applied to discover compounds with activity against ion channel targets. The method may include modulating the transmembrane potential of host cells in a plurality of sample wells with a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.Type: GrantFiled: February 2, 2004Date of Patent: December 6, 2011Assignee: Vertex Pharmaceuticals (San Diego) LLCInventors: Michael P. Maher, Jesus E. Gonzalez, III
-
Patent number: 7968545Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: GrantFiled: August 5, 2004Date of Patent: June 28, 2011Assignee: Vertex Pharmaceuticals Inc.Inventors: Dean M. Wilson, Andreas P. Termin, Timothy D. Neubert, Jian Wang, Yulian Zhang, Jesus E. Gonzalez, III, Esther Martinborough, Nicole Zimmerman
-
Patent number: 7923537Abstract: A method of characterizing the biological activity of a candidate compound may include exposing cells to the candidate compound, and then exposing the cells to a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.Type: GrantFiled: May 31, 2006Date of Patent: April 12, 2011Assignee: Vertex Pharmaceuticals (San Diego) LLCInventors: Michael P. Maher, Jesus E. Gonzalez, III
-
Publication number: 20110003814Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: ApplicationFiled: September 8, 2010Publication date: January 6, 2011Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Dean Mitchell Wilson, Esther Martinborough, Timothy Donald Neubert, Andreas Peter Termin, Jesus E. Gonzalez, III, Nicole Zimmerman
-
Patent number: 7816529Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: GrantFiled: July 2, 2004Date of Patent: October 19, 2010Assignee: Vertex Pharmaceuticals IncorporatedInventors: Dean Mitchell Wilson, Esther Martinborough, Timothy Donald Neubert, Andreas Peter Termin, Jesus E. Gonzalez, III, Nicole Zimmerman
-
Patent number: 7767408Abstract: A method of characterizing the biological activity of a candidate compound may include exposing cells to the candidate compound, and then exposing the cells to a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.Type: GrantFiled: May 31, 2006Date of Patent: August 3, 2010Assignee: Vertex Pharmaceuticals (San Diego) LLCInventors: Michael P. Maher, Jesus E. Gonzalez, III
-
Publication number: 20100160316Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: ApplicationFiled: March 1, 2010Publication date: June 24, 2010Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Jesus E. Gonzalez, III, Dean M. Wilson, Andreas P. Termin, Peter D. J. Grootenhuis, Yulian Zhang, Benjamin J. Petzoldt, Lev Tyler Dewey Fanning, Timothy D. Neubert, Roger D. Tung, Esther Martinborough, Nicole Zimmerman
-
Publication number: 20100144798Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.Type: ApplicationFiled: August 20, 2009Publication date: June 10, 2010Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Frederick F. VanGoor, Sara Sabina Hadida Ruah, Ashvani Kumar Singh, Eric R. Olson, Lewis Ray Makings, Jesus E. Gonzalez, III, James Arvid Rader, Fred Chambers, III, Mark Thomas Miller, Peter Diederik Jan Grootenhuis, Yahua Liu
-
Patent number: 7713983Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: GrantFiled: September 2, 2004Date of Patent: May 11, 2010Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jesus E. Gonzalez, III, Dean M. Wilson, Andreas P. Termin, Peter D. J. Grootenhuis, Yulian Zhang, Benjamin J. Petzoldt, Lev Tyler Dewey Fanning, Timothy D. Neubert, Roger D. Tung, Esther Martinborough, Nicole Zimmerman
-
Patent number: 7705031Abstract: The present invention relates to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the R1, Z, Y, RA, and W groups of formula I are as defined herein. The invention also provides pharmaceutically acceptable compositions and methods of using the compositions in the treatment of various disorders.Type: GrantFiled: November 1, 2007Date of Patent: April 27, 2010Assignee: Vertex Pharmaceuticals IncorporatedInventors: Dean M. Wilson, Andreas P. Termin, Jesus E. Gonzalez, III, Nicole Zimmermann, Yulian Zhang, Lev T. D. Fanning
-
Patent number: 7695922Abstract: A method of characterizing the biological activity of a candidate compound may include exposing cells to the candidate compound, and then exposing the cells to a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.Type: GrantFiled: May 30, 2006Date of Patent: April 13, 2010Assignee: Vertex Pharmaceuticals (San Diego) LLCInventors: Michael P. Maher, Jesus E. Gonzalez, III
-
Publication number: 20100087479Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: ApplicationFiled: September 10, 2009Publication date: April 8, 2010Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Jesus E. Gonzalez, III, Andreas P. Termin, Esther Martinborough, Nicole Zimmerman
-
Publication number: 20100081163Abstract: A method of characterizing the biological activity of a candidate compound may include exposing cells to the candidate compound, and then exposing the cells to a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.Type: ApplicationFiled: September 28, 2009Publication date: April 1, 2010Applicant: Vertex Pharmaceuticals (San Diego) LLCInventors: Michael P. Maher, Jesus E. Gonzalez, III
-
Patent number: 7687282Abstract: Methods and compositions are provided for determining the potential of a membrane. In one aspect, the method comprises: (a) introducing a first reagent comprising a hydrophobic fluorescent ion capable of redistributing from a first face of the membrane to a second face of the membrane in response to changes in the potential of the membrane, as described by the Nernst equation, (b) introducing a second reagent which labels the first face or the second face of the membrane, which second reagent comprises a chromophore capable of undergoing energy transfer by either (i) donating excited state energy to the fluorescent ion, or (ii) accepting excited state energy from the fluorescent ion, (c) exposing the membrane to radiation; (d) measuring energy transfer between the fluorescent ion and the second reagent, and (e) relating the energy transfer to the membrane potential. Energy transfer is typically measured by fluorescence resonance energy transfer.Type: GrantFiled: September 29, 2006Date of Patent: March 30, 2010Assignee: The Regents of the University of CaliforniaInventors: Roger Y. Tsien, Jesus E. Gonzalez, III